-
1
-
-
0024997911
-
Established anticonvulsants and treatment of refractory epilepsy
-
DOI 10.1016/0140-6736(90)91886-F
-
Brodie MJ,. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990; 336: 350-354. (Pubitemid 20264154)
-
(1990)
Lancet
, vol.336
, Issue.8711
, pp. 350-354
-
-
Brodie, M.J.1
-
2
-
-
0024988755
-
Treatment of epilepsy and febrile convulsions in children
-
DOI 10.1016/0140-6736(90)92025-D
-
Rylance GW,. Treatment of epilepsy and febrile convulsions in children. Lancet 1990; 336: 488-491. (Pubitemid 20264225)
-
(1990)
Lancet
, vol.336
, Issue.8713
, pp. 488-491
-
-
Rylance, G.W.1
-
3
-
-
0029826744
-
The new generation of antiepileptic drugs: Advantages and disadvantages
-
Perucca E,. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-543. (Pubitemid 26385257)
-
(1996)
British Journal of Clinical Pharmacology
, vol.42
, Issue.5
, pp. 531-543
-
-
Perucca, E.1
-
4
-
-
28544433841
-
Acute hyperammonemic coma with chronic valproic acid therapy
-
DOI 10.1345/aph.1G167
-
Cuturic M, Abramson RK,. Acute hyperammonemic coma with chronic valproic acid therapy. Ann Pharmacother 2005; 39: 2119-2123. (Pubitemid 41745961)
-
(2005)
Annals of Pharmacotherapy
, vol.39
, Issue.12
, pp. 2119-2123
-
-
Cuturic, M.1
Abramson, R.K.2
-
6
-
-
0020644555
-
Plasma protein-bindng and CSF concentrations of valproic acid in man following acute oral dosing
-
Rapeport WG, et al,. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing. Br J Clin Pharmacol 1983; 16: 365-369. (Pubitemid 13015759)
-
(1983)
British Journal of Clinical Pharmacology
, vol.16
, Issue.4
, pp. 365-369
-
-
Rapeport, W.G.1
Mendelow, A.D.2
French, G.3
-
7
-
-
0026769555
-
Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy
-
Lenn NJ, Robertson M,. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992; 42: 988-990.
-
(1992)
Neurology
, vol.42
, pp. 988-990
-
-
Lenn, N.J.1
Robertson, M.2
-
8
-
-
0024256069
-
Clinical pharmacokinetics of valproic acid
-
Zaccara G, et al,. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988; 15: 367-389.
-
(1988)
Clin Pharmacokinet
, vol.15
, pp. 367-389
-
-
Zaccara, G.1
-
9
-
-
0025854599
-
Nonlinear pharmacokinetics: Clinical implication
-
Ludden TM,. Nonlinear pharmacokinetics: clinical implication. Clin Pharmacokinet 1991; 20: 429-446.
-
(1991)
Clin Pharmacokinet
, vol.20
, pp. 429-446
-
-
Ludden, T.M.1
-
10
-
-
0031435886
-
Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: Lack of interaction in uremic serum caused by the presence of inhibitor
-
DOI 10.1097/00007691-199706000-00007
-
Dasgupta A, Luke M,. Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor. Ther Drug Monit 1997; 19: 281-285. (Pubitemid 28053482)
-
(1997)
Therapeutic Drug Monitoring
, vol.19
, Issue.3
, pp. 281-285
-
-
Dasgupta, A.1
Luke, M.2
-
11
-
-
0028355537
-
Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera: Role of uremic compounds
-
Dasgupta A, Jacques M,. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds. Am J Clin Pathol 1994; 101: 349-353. (Pubitemid 24089586)
-
(1994)
American Journal of Clinical Pathology
, vol.101
, Issue.3
, pp. 349-353
-
-
Dasgupta, A.1
Jacques, M.2
-
12
-
-
0029893728
-
Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: Presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions
-
Dasgupta A, Volk A,. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions. Ther Drug Monit 1996; 18: 284-287.
-
(1996)
Ther Drug Monit
, vol.18
, pp. 284-287
-
-
Dasgupta, A.1
Volk, A.2
-
13
-
-
0029809522
-
Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: Lack of interaction in uremic sera due to the presence of endogenous factors
-
DOI 10.1097/00007691-199612000-00005
-
Dasgupta A, Emerson L,. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit 1996; 18: 654-659. (Pubitemid 26404569)
-
(1996)
Therapeutic Drug Monitoring
, vol.18
, Issue.6
, pp. 654-659
-
-
Dasgupta, A.1
Emerson, L.2
-
14
-
-
0031886111
-
Factors affecting the free plasma fraction of phenytoin in patients with epilepsy
-
DOI 10.2165/00044011-199815020-00008
-
Jiménez MC, et al,. Factors affecting the free plasma fraction of phenytoin in patients with epilepsy. Clin Drug Investig 1998; 15: 153-157. (Pubitemid 28101495)
-
(1998)
Clinical Drug Investigation
, vol.15
, Issue.2
, pp. 153-157
-
-
Jimenez, M.C.1
Duran, J.A.2
Abadin, J.A.3
-
15
-
-
33747061542
-
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
-
DOI 10.1111/j.1742-7843.2006.pto-309.x
-
Joerger M, et al,. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol 2006; 99: 133-140. (Pubitemid 44213941)
-
(2006)
Basic and Clinical Pharmacology and Toxicology
, vol.99
, Issue.2
, pp. 133-140
-
-
Joerger, M.1
Huitema, A.D.R.2
Boogerd, W.3
Van Der Sande, J.J.4
Schellens, J.H.M.5
Beijnen, J.H.6
-
16
-
-
0015946877
-
Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease
-
Hooper WD, et al,. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974; 15: 276-282.
-
(1974)
Clin Pharmacol Ther
, vol.15
, pp. 276-282
-
-
Hooper, W.D.1
-
18
-
-
0018386980
-
Kinetics and metabolism of clobazam in animals and man
-
Volz M, et al,. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol 1979; 7: 41-50.
-
(1979)
Br J Clin Pharmacol
, vol.7
, pp. 41-50
-
-
Volz, M.1
-
19
-
-
0029837135
-
Evaluation of unbound serum carbamazepine and carbamazepine-10,11- epoxide concentration prediction methods in polytherapy adult patients with epilepsy
-
Kodama Y, et al,. Evaluation of unbound serum carbamazepine and carbamazepine-10,11-epoxide concentration prediction methods in polytherapy adult patients with epilepsy. Am J Ther 1996; 3: 699-707. (Pubitemid 26405036)
-
(1996)
American Journal of Therapeutics
, vol.3
, Issue.10
, pp. 699-707
-
-
Kodama, Y.1
Kuranari, M.2
Fujii, I.3
Kodama, H.4
Takeyama, M.5
-
20
-
-
0022354975
-
Effect of serum albumin on free fractions of phenobarbital and valproic acid in patients with convulsive seizures
-
Sadahiro N, et al,. Effect of serum albumin on free fractions of phenobarbital and valproic acid in patients with convulsive seizures. Brain Dev 1985; 7: 377-384. (Pubitemid 16247781)
-
(1985)
Brain and Development
, vol.7
, Issue.4
, pp. 377-384
-
-
Sadahiro, N.1
Kodama, S.2
Matsui, T.3
-
21
-
-
34247622195
-
Carnitine as an antidote for acute valproate toxicity in children
-
DOI 10.1097/MOP.0b013e32805e879a, PII 0000848020070400000016
-
Russell S,. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 2007; 19: 206-210. (Pubitemid 46668075)
-
(2007)
Current Opinion in Pediatrics
, vol.19
, Issue.2
, pp. 206-210
-
-
Russell, S.1
-
22
-
-
19544380424
-
L-carnitine was safely administered in the setting of valproate toxicity
-
LoVecchio F, et al,. L-carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med 2005; 23: 321-322.
-
(2005)
Am J Emerg Med
, vol.23
, pp. 321-322
-
-
Lovecchio, F.1
-
24
-
-
0026311514
-
Protein binding of L-carnitine family components
-
Marzo A, et al,. Protein binding of L-carnitine family components. Eur J Drug Metab Pharmacokinet 1991; 3: 364-368.
-
(1991)
Eur J Drug Metab Pharmacokinet
, vol.3
, pp. 364-368
-
-
Marzo, A.1
-
25
-
-
38349018462
-
Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children
-
Ueshima S, et al,. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. J Clin Pharm Ther 2008; 33: 31-38.
-
(2008)
J Clin Pharm Ther
, vol.33
, pp. 31-38
-
-
Ueshima, S.1
-
26
-
-
0036570112
-
Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy
-
Kodama Y, et al,. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy. Am J Health Syst Pharm 2002; 59: 835-840. (Pubitemid 34457200)
-
(2002)
American Journal of Health-System Pharmacy
, vol.59
, Issue.9
, pp. 835-840
-
-
Kodama, Y.1
Kodama, H.2
Kuranari, M.3
Tsutsumi, K.4
Ono, S.5
Yamaguchi, T.6
Fujimura, A.7
-
27
-
-
0033337583
-
No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy
-
Kodama Y, et al,. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy. J Clin Pharmacol 1999; 39: 1070-1076. (Pubitemid 30641867)
-
(1999)
Journal of Clinical Pharmacology
, vol.39
, Issue.10
, pp. 1070-1076
-
-
Kodama, Y.1
Kodama, H.2
Kuranari, M.3
Tsutsumi, K.4
Ono, S.5
Fujimura, A.6
|